Predictive Biotech – FDA Warning Letter, Aug 17, 2020
On August 17, 2020, the FDA issued a Warning Letter to Predictive Biotech, Inc. for marketing CoreCyte™, an umbilical cord-derived product, as a treatment, preventative, diagnostic, or cure for COVID-19. The FDA reviewed the company's websites (www.predictivebiotech.com, https://predtechgroup.com) and social media (www.facebook.com/PredictiveBiotech/) in August 2020.
CoreCyte™ is classified as a human cell, tissue, or cellular or tissue-based product (HCT/P) but fails to meet the criteria for regulation solely under section 361 of the PHS Act (42 U.S.C. § 264) and 21 C.F.R. Part 1271. Specifically, it does not qualify for homologous use (21 C.F.R. § 1271.10(a)(2) and 21 C.F.R. § 1271.3(c)) and appears to exceed minimal manipulation (21 C.F.R. § 1271.10(a)(1) and 21 C.F.R. § 1271.3(f)(1)).
Consequently, CoreCyte™ is deemed an unapproved new drug
ID · 4261adfe-c68d-411a-94ce-3dc880d313c9
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.